SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (6836)4/11/1998 12:41:00 AM
From: BigKNY3  Read Replies (1) | Respond to of 23519
 
VLAD: Dr. Casey may be anti-MUSE, but the patient posts seem very genuine. As a follow-up to a request, I have posted the first 5 patients reports on the "other" Vivus Board.

Message 4030656

Good Investing!

BigKNY3



To: VLAD who wrote (6836)4/11/1998 5:18:00 AM
From: Bruce Olsten  Read Replies (1) | Respond to of 23519
 
When Casey refers to MUSE delivery method of being less efficient that injection, he is remarking that the Caverject dose may be 10mcg, whereas for the same effect with MUSE the dose is 1000mcg. Why do you think it is stupid of him to conclude that urethral delivery is less efficient when you need a dose 100 times as strong!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News